This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): HuRx
Deal Structure: HuRx was originally developed by Northwest Biotherapeutics and is being co-developedwith Medarex.
In Northwest Biotherapeutics' 2004 10-K, it states that the product candidate (HuRx) has been acquired by Medarex and is in a FDA Phase I clinical trial.
In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash.
In September 2009, Bristol-Myers Squibb completed its acquisition of Medarex.
Partners: Northwest Biotherapeutics, Inc.
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: